---
document_datetime: 2024-01-09 16:52:32
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nexobrid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: nexobrid-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.928179
conversion_datetime: 2025-12-17 09:18:26.845578
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## NexoBrid

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------|
| II/0058              | Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as Study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, | 09/11/2023                          | 14/12/2023                                  | SmPC and PL                      | Please refer to Scientific Discussion 'NexoBrid-H-C-002246- II-Var.0058'. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | open label, 2 arm study aiming to demonstrate the superiority of NexoBrid treatment over SOC treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA). As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Annex II and Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to remove the black triangle from the SmPC and the package leaflet, combine the SmPCs and introduce minor editorial corrections to the product information. Version 9.4 of the RMP is acceptable. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0066             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 30/11/2023 | n/a |                                   |
| PSUSA/10028 /202212 | Periodic Safety Update EU Single assessment - concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/08/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0065             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/08/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0064   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                 | 28/04/2023   | n/a        |                   |                                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0057   | Submission of the 24-months' CSR addendum of the MW2010-03-02 (DETECT) category 1 study; a multicentre, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to gel vehicle and compared to standard of care. The provision of the CSR addresses the post-authorisation measure ANX 001.7. The updated RMP version 8.2 was considered acceptable. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 30/03/2023   | 14/12/2023 | SmPC and Annex II | SmPC section 5.1 is updated to include the 24 months results of study MW2010-03-02 (DETECT). Treatment with NexoBrid did not have clinically meaningful deleterious effect on burn scar cosmesis and function compared with the SOC treatment at 24 months after wound closure. |
| IA/0062   | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/02/2023   | n/a        |                   |                                                                                                                                                                                                                                                                                 |
| IA/0061/G | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                               | 15/02/2023   | n/a        |                   |                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS -   |            |            |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0060 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/01/2023 | 14/12/2023 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| R/0056   | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/06/2022   | 12/08/2022   | SmPC, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of NexoBrid in the approved indication remains favourable and therefore recommended the renewal of the marketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049  | Update of sections 4.2, 4.4, 4.8, 5.1, 5.2, 6.2 and 6.6 of the SmPC based on literature references and on interim results from study MW2010-03-02 (DETECT) listed as an obligation in the Annex II; this is a multicenter, multinational, randomized, controlled, assessor blinded, three-arm study performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and compared to Standard of Care. The submitted Clinical Study Report includes data of Acute Phase and 12 months Follow Up Period including sub-studies on PK parameters, immunogenicity and cardiac ECG testing. In addition, the MAH took the opportunity to revise the due date of the final study report for study MW2010-03-02 as agreed in procedure EMEA/H/C/002246/IB/0054. Furthermore, the PI is brought in line with the latest QRD template version 10.2. The Package Leaflet was updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 11/11/2021   | 21/06/2022   | SmPC and PL              | Based on interim results from study MW2010-03-02 (DETECT) and on literature references, SmPC sections 4.2, 4.4, 4.8, 5.1, 5.2, 6.2 and 6.6 were updated. The package leaflet was updated accordingly. The MAH initially proposed to extend the treatable wound area from 1 x 15% TBSA to 2 x 15% TBSA i.e. doubling the wound area for treatment to 30% TBSA in two treatment sessions. However, this was not agreed by CHMP as the safety database is currently considered insufficient and the submitted additional PK data are considered of minor relevance to support the extension of the treatable wound area from 1 x 15% TBSA to 2 x 15% TBSA. Thus, as stated in SmPC section 4.2, NexoBrid should not be applied to more than 15%. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IB/0055/G           | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   | 09/11/2021   | n/a        |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0054             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                           | 22/09/2021   | n/a        |                        |                                   |
| PSUSA/10028 /202012 | Periodic Safety Update EU Single assessment - concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                  | 02/09/2021   | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0053/G         | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.1 - Administrative change - Change in the name and/or address of the MAH                                                | 31/05/2021   | 21/06/2022 | SmPC, Labelling and PL |                                   |
| IA/0051/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished                                                                                  | 07/12/2020   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                                                                                                                                                                                                                                                                                                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure | 15/10/2020 | n/a |                                                                                                                                                                                                                                                                                                                               |
| II/0047   | Submission of the final study report for study MW2013-06-01, listed as a category 3 study in the RMP. This is an international, observational retrospective, data-collection study assessing efficacy of applied risk-minimisation measures in burn patients treated with NexoBrid. In addition, the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/09/2020 | n/a | The results from study MW2013-06-01 has achieved its primary goal and thus, the effectiveness of the implemented risk minimisation measures (RMMs) is considered shown. Even though only limited conclusions with respect to the extrapolation of the study results to non-participating EU countries are possible, the study |

<div style=\"page-break-after: always\"></div>

|           | MAH took the opportunity to revise the RMP in line with the new RMP template (GVP Rev. 2) and to change the due date for studies MW2013-06-01 and MW2010-03-02 (DETECT). The updated RMP version 7.1 is acceptable. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                  |            |     | provides evidence for a general effectiveness of the established additional RMMs.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------|
| IB/0048   | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 29/05/2020 | n/a |                                                                                     |
| IB/0046/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 27/02/2020 | n/a |                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0045/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   | 08/01/2020   | n/a        |                  |                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|----------------------------------------------------------|
| IB/0043             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                           | 06/08/2019   | n/a        |                  |                                                          |
| PSUSA/10028 /201812 | Periodic Safety Update EU Single assessment - concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                                         | 11/07/2019   | n/a        |                  | PRAC Recommendation - maintenance                        |
| N/0042              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                               | 11/06/2019   | 25/07/2019 | PL               |                                                          |
| N/0040              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                               | 25/04/2019   | 25/07/2019 | Labelling and PL |                                                          |
| IA/0039             | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                          | 17/01/2019   | n/a        |                  |                                                          |
| PSUSA/10028         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                  | 26/07/2018   | 28/09/2018 | SmPC and PL      | Refer to Scientific conclusions and grounds recommending |

<div style=\"page-break-after: always\"></div>

| /201712   | concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                                                                                                             |            |            |                 | the variation to terms of the Marketing Authorisation(s)' for PSUSA/10028/201712.                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0038 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                               | 09/08/2018 | 25/07/2019 | Annex II and PL |                                                                                                                                                                                                                                  |
| II/0035   | Update of section 6.6 of the SmPC to change the instructions for NexoBrid gel preparation. The package leaflet is updated accordingly. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability | 07/06/2018 | 28/09/2018 | SmPC and PL     | The instructions for use in the product information for the NexoBrid gel preparation (mixing powder with the gel) have been updated to delete the need to shake vigorously the preparation to fragment the NexoBrid powder cake. |
| IB/0033   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                        | 20/03/2018 | n/a        |                 |                                                                                                                                                                                                                                  |
| IB/0034   | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                        | 13/03/2018 | n/a        |                 |                                                                                                                                                                                                                                  |
| II/0032   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                        | 18/01/2018 | n/a        |                 |                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| R/0031              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                       | 14/09/2017   | 10/11/2017   | SmPC, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of NexoBrid in the approved indication remains favourable, and recommended the renewal of the marketing authorisation, but considered that another renewal in five years' time was needed based on the following pharmacovigilance grounds: an imposed additional pharmacovigilance study is ongoing, the results of which are expected to yield important new safety data which could impact on the benefit-risk balance of the product. Study MW2010-03-02, imposed at the time the initial MA was granted is outstanding and will study enzymatic debridement in burns patients (children and adults): a comparison to standard of care.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10028 /201612 | Periodic Safety Update EU Single assessment - concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                        | 20/07/2017   | 18/09/2017   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10028/201612.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0029             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                    | 26/01/2017   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0027/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - | 10/11/2016   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10028 /201512 | Periodic Safety Update EU Single assessment - concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/07/2016 | n/a | PRAC Recommendation - maintenance |
| II/0025             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                                                                                                                                       | 18/02/2016 | n/a |                                   |
| PSUSA/10028 /201412 | Periodic Safety Update EU Single assessment - concentrate of proteolytic enzymes enriched in bromelain                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/07/2015 | n/a | PRAC Recommendation - maintenance |
| IAIN/0022           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/04/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| PSUV/0018   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                            | 09/01/2015   | n/a        |      | PRAC Recommendation - maintenance   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------------|
| IA/0019/G   | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information | 30/10/2014   | n/a        |      |                                     |
| IB/0017     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                      | 04/08/2014   | n/a        |      |                                     |
| PSUV/0011   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                            | 10/07/2014   | n/a        |      | PRAC Recommendation - maintenance   |
| IB/0012     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                     | 23/06/2014   | n/a        |      |                                     |
| IA/0016     | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                       | 18/06/2014   | n/a        |      |                                     |
| IA/0015/G   | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.e.6.b - Change in any part of the (primary)                                                                                                                                                                                                                 | 18/06/2014   | 30/10/2014 | SmPC |                                     |

<div style=\"page-break-after: always\"></div>

|           | material not in contact with the finished formulation - Change that does not affect product information                                                                                                                                                                                                                                                                                                                                            |            |            |      | packaging product the   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------|
| II/0009   | to change the immediate packaging of the gel vehicule B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                               | 22/05/2014 | 30/10/2014 | SmPC |                         |
| IB/0014/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch place | 16/05/2014 | n/a        |      | control/testing takes   |
| IB/0010   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                               | 09/04/2014 | n/a        |      |                         |
| IA/0008   | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                                                                         | 20/02/2014 | n/a        |      |                         |

<div style=\"page-break-after: always\"></div>

| IA/0007     | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/02/2014   | n/a        |                       |                                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------|
| II/0006/G   | This was an application for a group of variations. This was an application for a group of variations to change the specifications limits for viscosity and the procedure for the determination of viscosity. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure | 20/02/2014   | n/a        |                       |                                   |
| PSUV/0003   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/01/2014   | n/a        |                       | PRAC Recommendation - maintenance |
| IAIN/0005   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/11/2013   | n/a        |                       |                                   |
| IAIN/0004/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/10/2013   | 30/10/2014 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to monitoring   |            |            |                        | arrangements additional   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------|
| T/0002    | Transfer of Marketing Authorisation from Teva Pharma GmbH to MediWound Germany GmbH. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                  | 31/07/2013 | 19/09/2013 | SmPC, Labelling and PL |                           |
| IAIN/0001 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/07/2013 | n/a        |                        |                           |